NO20061180L - Heteroarylkjedede pyridiner, pyraziner og pyrimidiner som CRF1-reseptorligander - Google Patents

Heteroarylkjedede pyridiner, pyraziner og pyrimidiner som CRF1-reseptorligander

Info

Publication number: NO20061180L
Authority: NO; Norway
Prior art keywords: disorders; compounds; crf; heteroberl; pyrazines
Prior art date: 2003-09-05

Application number

NO20061180A

Other languages

English (en)

Norwegian (no)

Inventor

Ping Ge

Raymond F Horvath

Bernd Kaiser

Yan Lu Zhang

Yasuchika Yamaguchi

Xuechun Zhang

Suoming Zhang

He Zhao

Stanly John

Neil Moorcroft

Greg Shutske

Original Assignee

Aventis Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-09-05

Filing date

2006-03-14

Publication date

2006-03-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34272952&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20061180(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-03-14 Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc

2006-03-31 Publication of NO20061180L publication Critical patent/NO20061180L/no

Links

108091005471 CRHR1 Proteins 0.000 title abstract 2
150000003230 pyrimidines Chemical class 0.000 title abstract 2
239000003446 ligand Substances 0.000 title 1
150000003216 pyrazines Chemical class 0.000 title 1
150000003222 pyridines Chemical class 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
208000035475 disorder Diseases 0.000 abstract 3
108010056643 Corticotropin-Releasing Hormone Receptors Proteins 0.000 abstract 2
KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 abstract 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
208000019901 Anxiety disease Diseases 0.000 abstract 1
208000024172 Cardiovascular disease Diseases 0.000 abstract 1
208000030814 Eating disease Diseases 0.000 abstract 1
208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 abstract 1
230000036506 anxiety Effects 0.000 abstract 1
235000014632 disordered eating Nutrition 0.000 abstract 1
125000001072 heteroaryl group Chemical group 0.000 abstract 1
230000004807 localization Effects 0.000 abstract 1
238000005259 measurement Methods 0.000 abstract 1
230000002093 peripheral effect Effects 0.000 abstract 1
239000000825 pharmaceutical preparation Substances 0.000 abstract 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 1
108020003175 receptors Proteins 0.000 abstract 1
102000005962 receptors Human genes 0.000 abstract 1
239000000523 sample Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Child & Adolescent Psychology (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Investigating Or Analysing Biological Materials (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

NO20061180A 2003-09-05 2006-03-14 Heteroarylkjedede pyridiner, pyraziner og pyrimidiner som CRF1-reseptorligander NO20061180L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US50041403P	2003-09-05	2003-09-05
PCT/US2004/028899 WO2005023806A2 (en)	2003-09-05	2004-09-03	Heteroaryl fused pyridines, pyrazines and pyrimidines as crf1 receptor ligands

Publications (1)

Publication Number	Publication Date
NO20061180L true NO20061180L (no)	2006-03-31

Family

ID=34272952

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20061180A NO20061180L (no)	2003-09-05	2006-03-14	Heteroarylkjedede pyridiner, pyraziner og pyrimidiner som CRF1-reseptorligander

Country Status (19)

Country	Link
US (2)	US20050113379A1 (pt)
EP (1)	EP1680424A2 (pt)
JP (1)	JP2007504271A (pt)
KR (1)	KR20060088534A (pt)
CN (1)	CN1878773A (pt)
AP (1)	AP2006003559A0 (pt)
AR (1)	AR045582A1 (pt)
AU (1)	AU2004270713A1 (pt)
BR (1)	BRPI0414087A (pt)
CA (1)	CA2537829A1 (pt)
CR (1)	CR8274A (pt)
EA (1)	EA200600372A1 (pt)
EC (1)	ECSP066408A (pt)
IL (1)	IL174084A0 (pt)
MA (1)	MA28086A1 (pt)
NO (1)	NO20061180L (pt)
TW (1)	TW200530232A (pt)
WO (1)	WO2005023806A2 (pt)
ZA (1)	ZA200601978B (pt)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005028480A2 (en) *	2003-09-03	2005-03-31	Neurogen Corporation	5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
JP5084725B2 (ja)	2005-06-06	2012-11-28	武田薬品工業株式会社	有機化合物
AU2006283940A1 (en)	2005-08-25	2007-03-01	F. Hoffmann-La Roche Ag	P38 MAP kinase inhibitors and methods for using the same
JP5147401B2 (ja)	2005-09-06	2013-02-20	塩野義製薬株式会社	Ｐｇｄ２受容体アンタゴニスト活性を有するインドールカルボン酸誘導体
US7405302B2 (en) *	2005-10-11	2008-07-29	Amira Pharmaceuticals, Inc.	5-lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en)	2005-11-04	2011-07-12	Amira Pharmaceuticals, Inc.	5-lipdxygenase-activating protein (FLAP) inhibitors
GB2431927B (en)	2005-11-04	2010-03-17	Amira Pharmaceuticals Inc	5-Lipoxygenase-activating protein (FLAP) inhibitors
ES2778846T3 (es)	2005-11-08	2020-08-12	Vertex Pharma	Moduladores heterocíclicos de transportadores de casete de unión a ATP
GB0525068D0 (en)	2005-12-08	2006-01-18	Novartis Ag	Organic compounds
WO2007069671A1 (ja)	2005-12-15	2007-06-21	Ono Pharmaceutical Co., Ltd.	二環式複素環化合物
WO2007133756A2 (en) *	2006-05-15	2007-11-22	Neurogen Corporation	Crf1 receptor ligands comprising heteroaryl fused bicycles
JO3235B1 (ar)	2006-05-26	2018-03-08	Astex Therapeutics Ltd	مركبات بيررولوبيريميدين و استعمالاتها
JP5837278B2 (ja)	2006-12-05	2015-12-24	イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−ＣｅｌｌｕｌａｒＴｈｅｒａｐｉｅｓ，Ｉｎｃ．	新規使用
WO2008076446A1 (en) *	2006-12-18	2008-06-26	Coleman Peter R	Accelerated opiate dependence detoxification process
CN101558072A (zh) *	2006-12-19	2009-10-14	霍夫曼-拉罗奇有限公司	吡唑并[3,4-d]嘧啶p38map激酶抑制剂
WO2008083070A1 (en) *	2006-12-29	2008-07-10	Neurogen Corporation	Crf1 receptor ligands comprising fused bicyclic heteroaryl moieties
CN102863432B (zh)	2007-05-09	2016-09-07	沃泰克斯药物股份有限公司	Cftr调节剂
JP5701608B2 (ja) *	2007-12-06	2015-04-15	イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−ＣｅｌｌｕｌａｒＴｈｅｒａｐｉｅｓ，Ｉｎｃ．	有機化合物
KR20150063170A (ko)	2007-12-07	2015-06-08	버텍스 파마슈티칼스 인코포레이티드	3-(6-(1-(2,2-디플루오로벤조[ｄ][1,3]디옥솔-5-일)사이클로프로판카복스아미도)-3-메틸피리딘-2-일)벤조산의 고체 형태
WO2009076142A2 (en) *	2007-12-07	2009-06-18	Vertex Pharmaceuticals Incorporated	Processes for producing cycloalkylcarboxiamido-pyridine benzoic acids
CN106432213A (zh)	2008-02-28	2017-02-22	沃泰克斯药物股份有限公司	作为cftr调节剂的杂芳基衍生物
KR101353857B1 (ko)	2008-08-22	2014-01-21	노파르티스 아게	Ｃｄｋ 억제제로서 피롤로피리미딘 화합물
BRPI0922808A2 (pt)	2008-12-06	2018-05-29	Intracellular Therapies Inc	compostos orgânicos
MX2011005933A (es)	2008-12-06	2011-12-16	Intra Cellular Therapies Inc	Compuestos organicos.
BRPI0922809A2 (pt)	2008-12-06	2018-05-29	Intracellular Therapies Inc	compostos orgânicos
EP2367430B1 (en)	2008-12-06	2014-08-13	Intra-Cellular Therapies, Inc.	Organic compounds
BRPI0922131A2 (pt) *	2008-12-06	2015-08-18	Intracellular Therapies Inc	Compostos orgânicos
EA201170773A1 (ru)	2008-12-06	2012-01-30	Интра-Селлулар Терапиз, Инк.	Органические соединения
US8349852B2 (en)	2009-01-13	2013-01-08	Novartis Ag	Quinazolinone derivatives useful as vanilloid antagonists
WO2010096426A2 (en) *	2009-02-20	2010-08-26	Emory University	Compounds, compositions, methods of synthesis, and methods of treatment
JP2012526810A (ja)	2009-05-13	2012-11-01	イントラ−セルラー・セラピーズ・インコーポレイテッド	有機化合物
CN102762572A (zh)	2010-02-01	2012-10-31	诺瓦提斯公司	作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物
AR080056A1 (es)	2010-02-01	2012-03-07	Novartis Ag	Derivados de ciclohexil-amida como antagonistas de los receptores de crf
JP5748777B2 (ja)	2010-02-02	2015-07-15	ノバルティスアーゲー	Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
UY33227A (es)	2010-02-19	2011-09-30	Novartis Ag	Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
BR112012026255A2 (pt)	2010-04-07	2017-03-14	Vertex Pharma	composições farmacêuticas de ácido 3-(6-(1-(2-,2-difluorbenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il)benzóico e administração das mesmas
WO2011153138A1 (en)	2010-05-31	2011-12-08	Intra-Cellular Therapies, Inc.	Organic compounds
EP2590657A4 (en)	2010-05-31	2014-02-12	Intra Cellular Therapies Inc	ORGANIC CONNECTIONS
US9434730B2 (en)	2010-05-31	2016-09-06	Intra-Cellular Therapies, Inc.	PDE1 inhibitor compounds
TW201206937A (en)	2010-05-31	2012-02-16	Intra Cellular Therapies Inc	Organic compounds
BR112013008240A2 (pt)	2010-10-08	2017-12-12	Abbvie Inc	compostos de furo [3-2-d] pirimidina
US8546416B2 (en)	2011-05-27	2013-10-01	Novartis Ag	3-spirocyclic piperidine derivatives as ghrelin receptor agonists
WO2012171016A1 (en)	2011-06-10	2012-12-13	Intra-Cellular Therapies, Inc.	Organic compounds
DK2806859T3 (da)	2012-01-25	2019-08-05	Vertex Pharma	Formuleringer af 3-(6-(1-(2.2-difluorbenzo[d][1,3]dioxol-5-yl) cyclopropancarboxamido)-3-methylpyridin-2-yl)benzoesyre
JP6140738B2 (ja) *	2012-03-06	2017-05-31	バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＧｍｂＨ	置換アザ二環およびその使用
CA2867043A1 (en)	2012-05-03	2013-11-07	Novartis Ag	L-malate salt of 2,7-diaza-spiro[4.5]dec-7-yle derivatives and crystalline forms thereof as ghrelin receptor agonists
EP2956141A4 (en)	2013-02-17	2016-10-26	Intra Cellular Therapies Inc	NEW USES
PL2970279T3 (pl)	2013-03-15	2021-05-31	Intra-Cellular Therapies, Inc.	Związki organiczne
EP2968338B1 (en)	2013-03-15	2019-01-09	Intra-Cellular Therapies, Inc.	Pde1 inhibitors for use in the treatment and/or prevention of cns injuries, and pns diseases, disorders or injuries
LT3033086T (lt)	2013-08-14	2021-12-27	Novartis Ag	Kombinuota terapija vėžiui gydyti
DK3068392T5 (da)	2013-11-12	2021-09-20	Vertex Pharma	Fremgangsmåde til fremstilling af farmaceutiske sammensætninger til behandlingen af cftr-medierede sygdomme
SI3102576T1 (sl)	2014-02-03	2019-08-30	Vitae Pharmaceuticals, Llc	Inhibitorji dihidropirolopiridina ROR-gama
EP2940022B1 (en) *	2014-04-30	2020-09-02	Masarykova Univerzita	Furopyridines as inhibitors of protein kinases
DK3157926T3 (da)	2014-06-20	2019-08-19	Intra Cellular Therapies Inc	Organiske forbindelser
US10285992B2 (en)	2014-08-07	2019-05-14	Intra-Cellular Therapies, Inc.	Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
US10131671B2 (en)	2014-08-07	2018-11-20	Intra-Cellular Therapies, Inc.	Organic compounds
RU2711442C2 (ru)	2014-09-17	2020-01-17	Интра-Селлулар Терапиз, Инк.	Соединения и способы
BR112017007460A2 (pt)	2014-10-14	2017-12-19	Vitae Pharmaceuticals Inc	inibidores de di-hidropirrolopiridina de ror-gama
US9845308B2 (en)	2014-11-05	2017-12-19	Vitae Pharmaceuticals, Inc.	Isoindoline inhibitors of ROR-gamma
US9663515B2 (en)	2014-11-05	2017-05-30	Vitae Pharmaceuticals, Inc.	Dihydropyrrolopyridine inhibitors of ROR-gamma
WO2016081556A1 (en)	2014-11-18	2016-05-26	Vertex Pharmaceuticals Incorporated	Process of conducting high throughput testing high performance liquid chromatography
TW201625635A (zh)	2014-11-21	2016-07-16	默沙東藥廠	作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物
ES2856931T3 (es)	2015-08-05	2021-09-28	Vitae Pharmaceuticals Llc	Moduladores de ROR-gamma
WO2017087608A1 (en)	2015-11-20	2017-05-26	Vitae Pharmaceuticals, Inc.	Modulators of ror-gamma
TWI757266B (zh)	2016-01-29	2022-03-11	美商維它藥物有限責任公司	ＲＯＲ－γ調節劑
US10682354B2 (en)	2016-03-28	2020-06-16	Intra-Cellular Therapies, Inc.	Compositions and methods
US9481674B1 (en)	2016-06-10	2016-11-01	Vitae Pharmaceuticals, Inc.	Dihydropyrrolopyridine inhibitors of ROR-gamma
AU2017324942B2 (en) *	2016-09-07	2022-01-27	The Regents Of The University Of California	Allosteric corticotropin-releasing factor receptor 1 (CRFR1) antagonists that decrease p-Tau and improve cognition
EP3509589B1 (en)	2016-09-12	2021-11-17	Intra-Cellular Therapies, Inc.	Novel uses
WO2019018975A1 (en)	2017-07-24	2019-01-31	Vitae Pharmaceuticals, Inc.	INHIBITORS OF ROR GAMMA
KR20200053481A (ko)	2017-07-24	2020-05-18	비타이 파마슈티컬즈, 엘엘씨	RORγ의 억제제
US11839614B2 (en)	2018-01-31	2023-12-12	Intra-Cellular Therapies, Inc.	Methods for treating or mitigating cardiotoxicity characterized by inhibition of adenosine A2 signaling and/or adenosine A2 receptor expression
CN110437846B (zh) *	2019-08-30	2022-02-25	陕西师范大学	含炔键的氟取代苯并噁唑液晶化合物及其制备方法
JP7612672B2 (ja)	2019-09-03	2025-01-14	イントラ－セルラー・セラピーズ・インコーポレイテッド	新規化合物
KR20220140515A (ko)	2020-01-13	2022-10-18	버지 애널리틱스, 인크.	치환된 피라졸로-피리미딘 및 그의 용도
US12364695B2 (en)	2020-06-02	2025-07-22	Intra-Cellular Therapies, Inc.	Methods of treating inflammatory disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1995010506A1 (en) *	1993-10-12	1995-04-20	The Du Pont Merck Pharmaceutical Company	1n-alkyl-n-arylpyrimidinamines and derivatives thereof
CA2194756A1 (en) *	1995-05-12	1996-11-14	Jun Yuan	Novel deazapurine derivatives; a new class of crf1 specific ligands
JP3964478B2 (ja) *	1995-06-30	2007-08-22	エーザイ・アール・アンド・ディー・マネジメント株式会社	ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
ES2273369T3 (es) *	1996-08-28	2007-05-01	Pfizer Inc.	Derivados 6,5 heterobiciclicos sustituidos.
EP1068206A1 (en) *	1998-04-02	2001-01-17	Neurogen Corporation	Aminoalkyl substituted pyrrolo 2,3-b]pyridine and pyrrolo 2,3-d]pyrimidine derivatives: modulators of crf1 receptors
US6828329B2 (en) *	2000-06-26	2004-12-07	Neurogen Corporation	Aryl fused substituted 4-oxy-pyridines
DE10229777A1 (de) *	2002-07-03	2004-01-29	Bayer Ag	Indolin-Phenylsulfonamid-Derivate
CN1809351A (zh) *	2003-04-24	2006-07-26	麦克公司	Akt活性抑制剂

2004
- 2004-09-03 AP AP2006003559A patent/AP2006003559A0/xx unknown
- 2004-09-03 CA CA002537829A patent/CA2537829A1/en not_active Abandoned
- 2004-09-03 US US10/933,834 patent/US20050113379A1/en not_active Abandoned
- 2004-09-03 AU AU2004270713A patent/AU2004270713A1/en not_active Abandoned
- 2004-09-03 WO PCT/US2004/028899 patent/WO2005023806A2/en not_active Ceased
- 2004-09-03 ZA ZA200601978A patent/ZA200601978B/en unknown
- 2004-09-03 CN CNA2004800327037A patent/CN1878773A/zh active Pending
- 2004-09-03 EP EP04788585A patent/EP1680424A2/en not_active Withdrawn
- 2004-09-03 JP JP2006526210A patent/JP2007504271A/ja active Pending
- 2004-09-03 BR BRPI0414087-7A patent/BRPI0414087A/pt not_active IP Right Cessation
- 2004-09-03 KR KR1020067004564A patent/KR20060088534A/ko not_active Withdrawn
- 2004-09-03 AR ARP040103174A patent/AR045582A1/es unknown
- 2004-09-03 EA EA200600372A patent/EA200600372A1/ru unknown
- 2004-09-06 TW TW093126841A patent/TW200530232A/zh unknown
2006
- 2006-03-02 IL IL174084A patent/IL174084A0/en unknown
- 2006-03-03 EC EC2006006408A patent/ECSP066408A/es unknown
- 2006-03-03 CR CR8274A patent/CR8274A/es unknown
- 2006-03-14 NO NO20061180A patent/NO20061180L/no not_active Application Discontinuation
- 2006-03-24 US US11/389,646 patent/US20060199823A1/en not_active Abandoned
- 2006-04-05 MA MA28916A patent/MA28086A1/fr unknown

Also Published As

Publication number	Publication date
CN1878773A (zh)	2006-12-13
EA200600372A1 (ru)	2006-08-25
IL174084A0 (en)	2008-02-09
WO2005023806A3 (en)	2005-06-02
ECSP066408A (es)	2006-09-18
ZA200601978B (en)	2007-05-30
AR045582A1 (es)	2005-11-02
US20050113379A1 (en)	2005-05-26
US20060199823A1 (en)	2006-09-07
EP1680424A2 (en)	2006-07-19
AP2006003559A0 (en)	2006-04-30
CR8274A (es)	2008-06-10
WO2005023806A2 (en)	2005-03-17
JP2007504271A (ja)	2007-03-01
MA28086A1 (fr)	2006-08-01
BRPI0414087A (pt)	2006-10-31
TW200530232A (en)	2005-09-16
CA2537829A1 (en)	2005-03-17
AU2004270713A1 (en)	2005-03-17
KR20060088534A (ko)	2006-08-04

Legal Events

Date	Code	Title	Description
2010-04-26	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20061180L (no)	2006-03-31	Heteroarylkjedede pyridiner, pyraziner og pyrimidiner som CRF1-reseptorligander
WO2005028480A3 (en)	2005-06-02	5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
NO20092668L (no)	2009-09-21	5-cyano-4-(pyrrolo [2,3B] pyridine-3-yl) -pyrimide derivatives useful as protein kinase inhibitors
BRPI0508220A (pt)	2007-07-17	derivados de pirazol heteroarila fundidos
BRPI0508036A (pt)	2007-07-17	derivados fundidos de pirazola
NO20054080L (no)	2005-11-21	Aminoheteroarylforbindelser som roteinkinaseinhibitorer
CY2017015I1 (el)	2017-09-13	ΕΤΕΡΟΑΡΥΛΟ ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ ΠΥΡΡΟΛΟ[2,3-b]ΠΥΡΙΔΙΝΕΣ ΚΑΙ ΠΥΡΡΟΛΟ[2,3-b]ΠΥΡΙΜΙΔΙΝΕΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΚΙΝΑΣΗΣ JANUS
WO2007013896A3 (en)	2007-05-31	Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors
ATE370139T1 (de)	2007-09-15	Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs
NO20074666L (no)	2007-11-09	Imidazo(1,2-A)pyridinforbindelser som VEGF-R2-inhibitorer
UY28970A1 (es)	2005-12-30	Compuestos moduladores de la actividad de c-kit y usos de los mismos
HUP0303283A2 (hu)	2004-01-28	Új piridinilcsoporttal szubsztituált pirazolopiridin-származékok, előállításuk és alkalmazásuk szív- és keringési betegségek kezelésére alkalmas gyógyszerkészítmény előállítására
NO20034122L (no)	2003-09-16	Sammensmeltede pyridinderivater for anvendelse som vanilloidreseptorantagonister for behandling av smerte
NO20051100L (no)	2005-05-02	Pyrazolsammensetninger anvendelige som GSK-3-inhibitorer
NO20072918L (no)	2007-07-05	Heteroaromatiske quinolinforbindelser, og anvendelse av disse som inhibitorer av PDE10
MEP46108A (en)	2011-02-10	2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES
MXPA04006271A (es)	2004-10-04	Derivados de indolinona utiles como inhibidores de la proteina cinasa.
CY1114989T1 (el)	2016-12-14	ΠΑΡΑΓΩΓΑ ΤΗΣ ΠΥΡΙΔΟ[2,3-d]ΠΥΡΙΜΙΔΙΝΗΣ, Η ΠΑΡΑΣΚΕΥΗ ΤΟΥΣ ΚΑΙ Η ΕΦΑΡΜΟΓΗ ΤΟΥΣ ΣΕ ΘΕΡΑΠΕΥΤΙΚΕΣ ΑΓΩΓΕΣ
WO2002014281A8 (en)	2002-04-04	Pyridine derivatives as inhibitors of p38
BG108427A (en)	2005-01-31	2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diaryl pyrimidines as crf1 receptor modulators
NO20080417L (no)	2008-03-18	Benzosykloheptapyridiner som inhibitorer av reseptortyrosinkinasen MET
NO20045025L (no)	2004-11-18	Nye forbindelser
MX2008001538A (es)	2008-04-04	Aril piridinas y metodos para su uso.
NO20072078L (no)	2007-05-31	Indolderivater som inhibitorer av loselig adenylsyklase
UA80474C2 (en)	2007-09-25	Aminoheteroaryl compounds as inhibitors of protein kinase